Source: The Business Journals: Austin

TFF Pharmaceuticals: TFF Pharmaceuticals could receive $210M for part in coronavirus treatment development

A promising treatment for the novel coronavirus could get a big boost from Austin scientists. TFF stands to make up to $210 million - and much more in royalties if the drug is widely adopted.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Glenn Mattes's photo - President & CEO of TFF Pharmaceuticals

President & CEO

Glenn Mattes

CEO Approval Rating

88/100

TFF Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic respiratory diseases. Read more